Abstract
In the last 20 years, tamoxifen has become the drug of choice in the treatment of breast carcinoma in both advanced and early stages. Furthermore, the ability of tamoxifen to prevent mammary carcinoma in the contralateral breast has prompted the creation of trials that include healthy patients with an increased risk of developing breast cancer with the purpose of verifying the drug's prophylactic action. As a consequence, a large number of healthy women or women with a long life expectancy are being treated with tamoxifen for long periods, making it crucial to study the possible long-term effects associated with this therapy. A weak estrogen-like effect of tamoxifen on the endometrium has been documented. This is supported by the increased incidence of glandular hyperplasia, polyps, carcinoma, and sarcoma in tamoxifen-treated patients. Some studies have shown that not all endometrial carcinomas arising in tamoxifen-treated patients have the favorable histologic and prognostic features typical of estrogen-associated endometrial cancers. This, in conjunction with the demonstrated carcinogenicity of tamoxifen in some animal models, indicates the need for caution in the use of this drug and makes strict gynecologic surveillance of tamoxifen-treated patients imperative.
| Original language | English |
|---|---|
| Pages (from-to) | 53-70 |
| Number of pages | 18 |
| Journal | Anatomic pathology (Chicago, Ill. : annual) |
| Volume | 2 |
| Publication status | Published - 1997 |
Fingerprint
Cite this
Uterine pathology in tamoxifen-treated patients with breast cancer. / Carcangiu, M. L.
In: Anatomic pathology (Chicago, Ill. : annual), Vol. 2, 1997, p. 53-70.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Uterine pathology in tamoxifen-treated patients with breast cancer.
AU - Carcangiu, M. L.
PY - 1997
Y1 - 1997
N2 - In the last 20 years, tamoxifen has become the drug of choice in the treatment of breast carcinoma in both advanced and early stages. Furthermore, the ability of tamoxifen to prevent mammary carcinoma in the contralateral breast has prompted the creation of trials that include healthy patients with an increased risk of developing breast cancer with the purpose of verifying the drug's prophylactic action. As a consequence, a large number of healthy women or women with a long life expectancy are being treated with tamoxifen for long periods, making it crucial to study the possible long-term effects associated with this therapy. A weak estrogen-like effect of tamoxifen on the endometrium has been documented. This is supported by the increased incidence of glandular hyperplasia, polyps, carcinoma, and sarcoma in tamoxifen-treated patients. Some studies have shown that not all endometrial carcinomas arising in tamoxifen-treated patients have the favorable histologic and prognostic features typical of estrogen-associated endometrial cancers. This, in conjunction with the demonstrated carcinogenicity of tamoxifen in some animal models, indicates the need for caution in the use of this drug and makes strict gynecologic surveillance of tamoxifen-treated patients imperative.
AB - In the last 20 years, tamoxifen has become the drug of choice in the treatment of breast carcinoma in both advanced and early stages. Furthermore, the ability of tamoxifen to prevent mammary carcinoma in the contralateral breast has prompted the creation of trials that include healthy patients with an increased risk of developing breast cancer with the purpose of verifying the drug's prophylactic action. As a consequence, a large number of healthy women or women with a long life expectancy are being treated with tamoxifen for long periods, making it crucial to study the possible long-term effects associated with this therapy. A weak estrogen-like effect of tamoxifen on the endometrium has been documented. This is supported by the increased incidence of glandular hyperplasia, polyps, carcinoma, and sarcoma in tamoxifen-treated patients. Some studies have shown that not all endometrial carcinomas arising in tamoxifen-treated patients have the favorable histologic and prognostic features typical of estrogen-associated endometrial cancers. This, in conjunction with the demonstrated carcinogenicity of tamoxifen in some animal models, indicates the need for caution in the use of this drug and makes strict gynecologic surveillance of tamoxifen-treated patients imperative.
UR - http://www.scopus.com/inward/record.url?scp=0031324252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031324252&partnerID=8YFLogxK
M3 - Article
C2 - 9575370
AN - SCOPUS:0031324252
VL - 2
SP - 53
EP - 70
JO - Anatomic pathology (Chicago, Ill. : annual)
JF - Anatomic pathology (Chicago, Ill. : annual)
SN - 1056-5884
ER -